WAY-267464 (original) (raw)
WAY-267464 is a potent, selective, non-peptide agonist for the oxytocin receptor, with negligible affinity for the vasopressin receptors. Contradictorily however, though originally described as selective for the oxytocin receptor and lacking affinity for the vasopressin receptors, it has since been reported to also act as a potent vasopressin V1A receptor antagonist (in contrast to oxytocin, which is a weak agonist of the V1A receptor). WAY-267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin, and in animal tests produces centrally-mediated oxytocinergic actions such as anxiolytic effects, but with no antidepressant effect evident. It was developed by a team at Ferring Pharmaceuticals.
| Property | Value |
|---|---|
| dbo:abstract | WAY-267464 is a potent, selective, non-peptide agonist for the oxytocin receptor, with negligible affinity for the vasopressin receptors. Contradictorily however, though originally described as selective for the oxytocin receptor and lacking affinity for the vasopressin receptors, it has since been reported to also act as a potent vasopressin V1A receptor antagonist (in contrast to oxytocin, which is a weak agonist of the V1A receptor). WAY-267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin, and in animal tests produces centrally-mediated oxytocinergic actions such as anxiolytic effects, but with no antidepressant effect evident. It was developed by a team at Ferring Pharmaceuticals. WAY-267464 is or was under investigation for the potential clinical treatment of anxiety disorders by Wyeth.[1] (en) |
| dbo:casNumber | 847375-16-0 |
| dbo:fdaUniiCode | XXL55X3DKM |
| dbo:pubchem | 9938214 |
| dbo:thumbnail | wiki-commons:Special:FilePath/WAY-267464.svg?width=300 |
| dbo:wikiPageExternalLink | http://adisinsight.springer.com/drugs/800029344 |
| dbo:wikiPageID | 23858376 (xsd:integer) |
| dbo:wikiPageLength | 4846 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1109032567 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Non-peptide dbr:Anxiety_disorder dbc:Piperazines dbc:Resorcinols dbr:Antidepressant dbr:Anxiolytic dbr:Receptor_antagonist dbr:Oxytocin_receptor dbr:Agonist dbc:Anxiolytics dbc:Benzamides dbr:Ferring_Pharmaceuticals dbr:Oxytocin dbc:Oxytocin_receptor_agonists dbc:Vasopressin_receptor_antagonists dbr:Affinity_(pharmacology) dbr:Wyeth dbr:TC_OT_39 dbr:Vasopressin_receptor dbr:Vasopressin_V1A_receptor dbr:Blood-brain-barrier dbr:Oxytocinergic |
| dbp:atcPrefix | none (en) |
| dbp:c | 32 (xsd:integer) |
| dbp:casNumber | 847375 (xsd:integer) |
| dbp:chemspiderid | 31047382 (xsd:integer) |
| dbp:h | 35 (xsd:integer) |
| dbp:iupacName | 4 (xsd:integer) |
| dbp:legalStatus | Uncontrolled (en) |
| dbp:n | 7 (xsd:integer) |
| dbp:o | 4 (xsd:integer) |
| dbp:pubchem | 9938214 (xsd:integer) |
| dbp:routesOfAdministration | ? (en) |
| dbp:smiles | OC1=CC=CC=C1 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | HWPGRFRXZNLZEX-UHFFFAOYSA-N (en) |
| dbp:unii | XXL55X3DKM (en) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 451221682 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Genito-urinary-drug-stub dbt:Nervous-system-drug-stub dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Fdacite dbt:Stdinchicite dbt:Oxytocin_and_vasopressin_receptor_modulators |
| dcterms:subject | dbc:Piperazines dbc:Resorcinols dbc:Anxiolytics dbc:Benzamides dbc:Oxytocin_receptor_agonists dbc:Vasopressin_receptor_antagonists |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | WAY-267464 is a potent, selective, non-peptide agonist for the oxytocin receptor, with negligible affinity for the vasopressin receptors. Contradictorily however, though originally described as selective for the oxytocin receptor and lacking affinity for the vasopressin receptors, it has since been reported to also act as a potent vasopressin V1A receptor antagonist (in contrast to oxytocin, which is a weak agonist of the V1A receptor). WAY-267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin, and in animal tests produces centrally-mediated oxytocinergic actions such as anxiolytic effects, but with no antidepressant effect evident. It was developed by a team at Ferring Pharmaceuticals. (en) |
| rdfs:label | WAY-267464 (en) |
| owl:sameAs | yago-res:WAY-267464 wikidata:WAY-267464 dbpedia-sh:WAY-267464 dbpedia-sr:WAY-267464 https://global.dbpedia.org/id/4xh7P |
| prov:wasDerivedFrom | wikipedia-en:WAY-267464?oldid=1109032567&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/WAY-267464.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:WAY-267464 |
| is dbo:wikiPageRedirects of | dbr:C32H35N7O4 dbr:WAY-267,464 |
| is dbo:wikiPageWikiLink of | dbr:C32H35N7O4 dbr:WAY-267,464 |
| is foaf:primaryTopic of | wikipedia-en:WAY-267464 |
